|
| All patients (N = 60) | COX2 | p-value | Cyclin D1 | p-value | p21 | p-value | ||||||||
| Low (N = 29) | High (N = 31) | Low (N = 31) | High (N = 29) | Low (N = 29) | High (N = 31) | ||||||||||
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||||||||
| Sex |
|
|
|
|
|
|
|
|
|
| |||||
| Male | 36 (60%) | 18 (50%) | 18 (50%) | 0.752‡ | 16 (44.4%) | 20 (55.6%) | 0.170‡ | 21 (58.3%) | 15 (41.7%) | 0.058‡ | |||||
| Female | 24 (40%) | 11 (45.8%) | 13 (54.2%) | 15 (62.5%) | 9 (37.5%) | 8 (33.3%) | 16 (66.7%) | ||||||||
| Age (year) |
|
|
|
|
|
|
|
|
|
| |||||
| Mean ± SD | 58.33 ± 12.27 | 57.10 ± 11.66 | 59.48 ± 12.90 | 0.378 | 56.90 ± 11.74 | 59.86 ± 12.84 | 0.355* | 59.13 ± 13.90 | 57.58 ± 10.70 | 0.627* | |||||
| Median (Range) | 60 (29 - 80) | 55 (30 - 80) | 62 (29 - 75) | 55 (29 - 75) | 64 (32 - 80) | 60 (29 - 80) | 55 (30 - 75) | ||||||||
| Initial site |
|
|
|
|
|
|
|
|
|
| |||||
| Ascending | 19 (31.7%) | 4 (21.1%) | 15 (78.9%) | 0.034‡ | 3 (15.8%) | 16 (84.2%) | 0.001‡ | 13 (68.4%) | 6 (31.6%) | 0.017‡ | |||||
| Transverse | 6 (10%) | 3 (50%) | 3 (50%) | 3 (50%) | 3 (50%) | 5 (83.3%) | 1 (16.7%) | ||||||||
| Descending | 5 (8.3%) | 3 (60%) | 2 (40%) | 4 (80%) | 1 (20%) | 2 (40%) | 3 (60%) | ||||||||
| Rectosigmoid | 30 (50%) | 19 (63.3%) | 11 (36.7%) | 21 (70%) | 9 (30%) | 9 (30%) | 21 (70%) | ||||||||
| Size |
|
|
|
|
|
|
|
|
|
| |||||
| ≤5 cm | 27 (45%) | 22 (81.5%) | 5 (18.5%) | <0.001‡ | 22 (81.5%) | 5 (18.5%) | <0.001‡ | 5 (18.5%) | 22 (81.5%) | <0.001‡ | |||||
| > 5 cm | 33 (55%) | 7 | (21.2%) | 26 (78.8%) | 9 (27.3%) | 24 (72.7%) | 24 (72.7%) | 9(27.3%) | |||||||
| Pathological type |
|
|
|
|
|
|
|
|
|
| |||||
| Conventional | 52 (86.7%) | 28 (53.8%) | 24 (46.2%) | 0.053‡ | 28 (53.8%) | 24 (46.2%) | 0.465‡ | 22 (42.3%) | 30 (57.7%) | 0.024‡ | |||||
| Mucoid | 8 (13.3%) | 1 (12.5%) | 7 (87.5%) | 3 (37.5%) | 5 (62.5%) | 7 (87.5%) | 1 (12.5%) | ||||||||
| Grade |
|
|
|
|
|
|
|
|
|
| |||||
| Grade I | 13 (21.7%) | 13 (100%) | 0 (0%) | <0.001§ | 13 (100%) | 0 (0%) | <0.001§ | 2 (15.4%) | 11 (84.6%) | <0.001§ | |||||
| Grade II | 31 (51.7%) | 14 (45.2%) | 17 (54.8%) | 13 (41.9%) | 18 (58.1%) | 14 (45.2%) | 17 (54.8%) | ||||||||
| Grade III | 16 (26.7%) | 2 (12.5%) | 14 (87.5%) | 5 (31.3%) | 11 (68.8%) | 13 (81.3%) | 3 (18.8%) | ||||||||
| T |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| T1 | 9 (15%) | 9 (100%) | 0 (0%) | <0.001§ | 9 (100%) | 0 (0%) | <0.001§ | 0 (0%) | 9 (100%) | <0.001§ | |||||
| T2 | 14 (23.3%) | 10 (71.4%) | 4 (28.6%) | 11 (78.6%) | 3 (21.4%) | 4 (28.6%) | 10 (71.4%) | ||||||||
| T3 | 12 (20%) | 4 (33.3%) | 8 (66.7%) | 5 (41.7%) | 7 (58.3%) | 6 (50%) | 6 (50%) | ||||||||
| T4 | 25 (41.7%) | 6 (24%) | 19 (76%) | 6 (24%) | 19 (76%) | 19 (76%) | 6 (24%) | ||||||||
| LN metastasis |
|
|
|
|
|
|
|
|
|
|
|
| |||
| Node negative | 26 (43.3%) | 22 (84.6%) | 4 (15.4%) | <0.001‡ | 21 (80.8%) | 5 (19.2%) | <0.001‡ | 5 (19.2%) | 21 (80.8%) | <0.001‡ | |||||
| Node positive | 34 (56.7%) | 7 (20.6%) | 27 (79.4%) | 10 (29.4%) | 24 (70.6%) | 24 (70.6%) | 10 (29.4%) | ||||||||
| Distant metastasis |
|
|
|
|
|
|
|
|
|
| |||||
| Absent | 43 (71.7%) | 27 (62.8%) | 16 (37.2%) | <0.001‡ | 26 (60.5%) | 17 (39.5%) | 0.030‡ | 15 (34.9%) | 28 (65.1%) | 0.001‡ | |||||
| Present | 17 (28.3%) | 2 (11.8%) | 15 (88.2%) | 5 (29.4%) | 12 (70.6%) | 14 (82.4%) | 3 (17.6%) | ||||||||
| Duke’s stage |
|
|
|
|
|
|
|
|
|
| |||||
| Stage A | 14 (23.3%) | 14 (100%) | 0 (0%) | <0.001§ | 14 (100%) | 0 (0%) | <0.001§ | 2 (14.3%) | 12 (85.7%) | <0.001§ | |||||
| Stage B | 11 (18.3%) | 7 (63.6%) | 4 (36.4%) | 6 (54.5%) | 5 (45.5%) | 3 (27.3%) | 8 (72.7%) | ||||||||